CRVS stock gains 14% on initiating a registrational study on its lead candidate, soquelitinib, to treat relapsed/refractory peripheral T-cell...
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Rubriques :
Maroc - ZACKS.COM - All Stories - 20/Aug 17:04
Bristol Myers' (BMY) Breyanzi Label Expansion Application Validated
Bristol Myers' (BMY) application to expand Breyanzi's label for the treatment of adult patients with relapsed or refractory follicular lymphoma gets EMA validation.
Articles similaires
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
zacks.com - 13:00
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Bristol Myers Squibb (BMY) Falls More Steeply Than Broader Market: What Investors Need to Know
zacks.com - 05/Sep 21:45
Bristol Myers Squibb (BMY) closed at $49.80 in the latest trading session, marking a -0.32% move from the prior day.
Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
drugs.com - 03/Sep 01:09
LOS ALTOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing...
Weight Reduction Varies for Patients Receiving Semaglutide, Liraglutide
drugs.com - 13/Sep 15:09
FRIDAY, Sept. 13, 2024 -- For patients with obesity receiving semaglutide or liraglutide, weight reduction at one year is associated with medication...
Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know
zacks.com - 11/Sep 21:45
In the most recent trading session, Bristol Myers Squibb (BMY) closed at $48.59, indicating a -1.4% shift from the previous trading day.
FDA Grants Label Expansion to J&J's Tremfya in Ulcerative Colitis
zacks.com - 12/Sep 15:39
With this latest approval, JNJ's Tremfya is approved for a total of three immunology indications.
FDA Grants Label Expansion to J&J's Tremfya in Ulcerative Colitis
zacks.com - 12/Sep 15:39
With this latest approval, JNJ's Tremfya is approved for a total of three immunology indications.
Les derniers communiqués
-
Adobe Brings Conversational AI to Trillions of PDFs with the New AI Assistant in Reader and Acrobat
Adobe - 21/02/2024
-
Laura Frigenti takes the Helm as Chief Executive Officer of the Global Partnership for Education
Global Partnership for Education - 05/12/2022